Cargando…
Cardiotoxicity Secondary to Immune Checkpoint Inhibitors in the Elderly: Safety in Real-World Data
SIMPLE SUMMARY: Immunotherapy is the mainstay treatment for most solid tumours. However, its cardiotoxicity is not yet known and studied, and its uncertainty is even greater in elderly patients. For this reason, this ambispective study was conducted in 195 patients over 70 years of age who were trea...
Autores principales: | Toribio-García, Irene, Olivares-Hernández, Alejandro, Miramontes-González, José Pablo, Domínguez, Luis Posado, Martín García, Ana, Eiros Bachiller, Rocío, Figuero-Pérez, Luis, Garijo Martínez, María, Roldán Ruiz, Jonnathan, Bellido Hernández, Lorena, Fonseca-Sánchez, Emilio, Luis Sánchez, Pedro, del Barco-Morillo, Edel |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10486692/ https://www.ncbi.nlm.nih.gov/pubmed/37686569 http://dx.doi.org/10.3390/cancers15174293 |
Ejemplares similares
-
Influence of DNA Mismatch Repair (MMR) System in Survival and Response to Immune Checkpoint Inhibitors (ICIs) in Non-Small Cell Lung Cancer (NSCLC): Retrospective Analysis
por: Olivares-Hernández, Alejandro, et al.
Publicado: (2022) -
Immune System Disorders, Cancer and Viral Infections: A New Treatment Opportunity for the Immune Checkpoint Inhibitors
por: Olivares-Hernández, Alejandro, et al.
Publicado: (2021) -
Immune checkpoint inhibitors in non-small cell lung cancer: from current perspectives to future treatments—a systematic review
por: Olivares-Hernández, Alejandro, et al.
Publicado: (2023) -
The relationship between PARP inhibitors with the relapse and leukemisation of lymphomas: a case report
por: Navalón-Jiménez, Marta, et al.
Publicado: (2023) -
Resistance to Immune Checkpoint Inhibitors Secondary to Myeloid-Derived Suppressor Cells: A New Therapeutic Targeting of Haematological Malignancies
por: Olivares-Hernández, Alejandro, et al.
Publicado: (2021)